Open

Coming up

Don't miss

Replay


LATEST SHOWS

FOCUS

One year on, what has Maidan changed in Ukraine?

Read more

WEB NEWS

Web users react to Ferguson grand jury decision

Read more

WEB NEWS

USA: Online reactions to the death of Tamir Rice

Read more

MIDDLE EAST MATTERS

Israel: Business is booming in gun shops

Read more

TALKING EUROPE

Monica Macovei, Former Romanian justice minister

Read more

IN THE PAPERS

'Inconsistency was the only constant with evidence in Michael Brown's case'

Read more

AFRICA NEWS

Nigeria: Two female bombers kill at least 30 in Maiduguri

Read more

IN THE PAPERS

Sarkozy: 'My first challenge will be to bring my political family back together'

Read more

THE INTERVIEW

Tunisia’s Essebsi says ready to form pluralist govt

Read more

Researchers zero in on Alzheimer's plaque origin

Latest update : 2008-04-09

Researchers have found a key ingredient, produced by a brain cell activity, for the formation of Alzheimer's plaques.

Researchers have found that a key ingredient for the formation of Alzheimer's plaques is produced by a brain cell activity, according to a study that helps understand the disease's origin.

The ability of brain cells to absorb substances from their surface, a process called endocytosis, is essential to producing amyloid beta, a protein fragment that clusters together to form Alzheimer's plaques, said the study released Wednesday.

The researchers found that by giving a drug that blocks endocytosis to a mouse with Alzheimer's disease, levels of amyloid beta sank by 70 percent, according to the study published in the journal Neuron.

But using the drug to treat Alzheimer's is not an option because brain cells need to be able to take in substances from the surface, said the neuroscientists at Washington University School of Medicine in St. Louis.

"Blocking endocytosis isn't a viable option for treatment because cells throughout the body, including brain cells, need endocytosis for healthy function," said the study's first author, John Cirrito, research instructor in neurology.

"But we are starting to understand the origins of amyloid beta in more detail now, and what we're learning is opening other options we can pursue to seek new treatments for Alzheimer's disease," he said.

The researchers believe the brain cells may be accidentally taking in amyloid precursor protein (APP), which breaks down into amyloid beta.

In that case, they said, a drug that reduces APP intake could help reduce production of amyloid beta.
 

Date created : 2008-04-09

COMMENT(S)